genOway signs exclusive distribution agreement with American Taconic Biosciences
Lyon-based company genOway has concluded an exclusive distribution agreement with American Taconic Biosciences. The transaction concerns the United States market, which already represents more than 50% of the group's sales.
genOway, specialized in the design of genetically modified preclinical models (mice, rats and cell lines), announced on September 23, 2026 the signing of an exclusive distribution agreement with Taconic Biosciences.
Taconic Biosciences is presented as one of the American players in preclinical research models, with commercial coverage across the entire United States market. This market constitutes genOway's primary outlet, accounting for more than 50% of its sales.
Based in Lyon, genOway was founded in 1999 and operates in more than 28 countries across North America, Europe and Asia.
A model based on the resale of genOway products
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The economic model of the agreement is based on the resale, by Taconic Biosciences, of products purchased from genOway. Each sale realized by Taconic thus translates into additional revenue for the company.
According to genOway, the financial terms of the agreement make it possible to preserve profitability close to that of direct sales.
Continuation and acceleration of commercial investments in the United States
genOway indicates that this agreement is synergistic with the commercial investments made over the past twelve months. Beyond this distribution partnership, the company continues and accelerates its commercial investments in the American market, focusing on its key partners and clients.
SectorPharmacie et biotechnologies›Biotechnologies
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 8,4 millions d'euros
Quarterly revenue: 8,4 millions d'euros
Net income: -2,9 millions d'euros
11 millions d'euros
Guidance from the release
« Poursuivant son plan stratégique ROUTE50+data, genOway confirme l'objectif de 50 M€ de revenus en 2028. » ; « la Société anticipe une croissance d'environ +15 % de son chiffre d'affaires des Modèles Catalogue au 2nd semestre après +7% enregistré au 1er semestre »
Risks mentioned
Concurrence sévère des acteurs asiatiques dans l'activité Modèle Sur Mesure.
Environnement biotech américain particulièrement difficile ces derniers trimestres.
Opportunities identified
Accélération de la croissance visée au 2nd semestre, portée par l'essor de genOway Shanghai.
Lancement de nouveaux Modèles Catalogue en 2025.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
